Teva appoints general manager in Germany
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has made several appointments in Germany following its acquisition of Ratiopharm. It appointed Dr Sven Dethlefs, previously CEO of Teva Germany, as general manager of Ratiopharm. Oliver Windholz, Ratiopharm's former chairman, will oversee integration of Teva's European headquarters in Utrecht, the Netherlands, as chief operating officer until the end of this year, after which will leave the company. Dr Walter Buhl will continue as head of production in Germany, and Dr Gerald Huber will take over Teva's R&D operations in Europe. Dr Hermann Allgaier will head late-stage commercial production of Ratiopharm's biopharmaceutical and biogeneric products after its integration into Teva's business, and Dr Karl Heinz Emmert will be responsible for the development of biosimilars.